Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.
Leukemia|Lymphoma
DRUG: Forodesine Hydrochloride Sterile Solution, 5 mg/mL|DRUG: Forodesine Hydrochloride Capsules (100 mg)
To determine the rate of complete remission for T lymphoblastic leukemia/lymphoma relapsed or refractory patients. The complete remission rate will be evaluated over the three-month Initial Treatment Period.
To determine the rate of CR achieved based on prior HSCT status|Assess safety and tolerability|Assess survival end points|Evaluate the maintenance and duration of response|Evaluate the proportion of patients able to proceed to HSCT|Evaluate the effects of this forodesine regimen on plasma levels of dGuo|Determine the effects of this forodesine regimen on clinical end points|Explore potential predictive biomarkers
The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.